October 2015

Links Newsletter

The latest news, service information, tips and industry insight from our staff of professionals at ACM Medical Laboratory

ACM Medical Laboratory

ICD10 Codes Required on All Test Orders Starting October 1, 2015!

ACM requires ICD10 diagnosis codes for all test orders starting October 1, 2015. http://acmlab.com/Physician-Services/ICD10-Preparedness.aspx.

ICD9-ICD10 Conversion

For assistance with ICD9 to ICD10 coding conversion, go to - https://www.aapc.com/icd-10/widgets/add-codeconverter-widget.aspx

ACM Medical Laboratory Implements Group B Streptococcus Prenatal Screening by PCR

Suzanne E. Dale, PhD, D(ABMM) Director, Microbiology and Molecular Diagnostics

ACM Medical Laboratory is proud to offer the BD MAX GBS Assay, a culture-enriched polymerase chain reaction (PCR)-based test that is approved by the FDA to detect Group B Streptococcus colonization in pregnant women. Enriched PCR screening is a CDC-recommended approach for GBS prenatal screening and is the most accurate test to identify GBS colonization. The PCR test is performed using the same vaginal/rectal swabs used in culture methods, so there are no collection differences for Providers. The benefits of the enriched PCR method are improved sensitivity and the ability to detect non-hemolytic GBS isolates that may be missed by traditional culture-based screening methods.

Two test options will be offered: 1) Enriched GBS Screening Only (Test code: 3174) and 2) Enriched GBS Screening with Reflex to Susceptibility Testing (Test code: 8089). The Reflex Test is suitable for patients who are penicillin-allergic and will provide susceptibility results for erythromycin and clindamycin.

For additional information please refer to: http://acmlab.com/Resource-Library/

ACM Medical Laboratory Validates the Performance of a New C. trachomatis (CT) and Neisseria gonorrhoeae (NG) Amplified (NAAT) Assay

Suzanne E. Dale, PhD, D(ABMM) Director, Microbiology and Molecular Diagnostics

ACM Medical Laboratory will begin to transition clients to a new CT/NG Nucleic Acid Amplification Test (NAAT). The testing will be performed using the Roche cobas® 4800 system, which is a PCR-based amplification assay. ACM has performed an extensive validation to show that the Roche cobas® CT/NG is as sensitive and specific as the Hologic Aptima CT/GC assay. An advantage specific to the Roche cobas® CT/NG test includes dual-target detection, whereby CT/NG mutants are more likely to be detected.

ACM Medical Laboratory has verified the performance of endocervical, vaginal, male/female urine collections and PreservCyt® (ThinPrep™) Pap specimens. In addition, ACM Medical Laboratory has validated "off-label" sources including oropharyngeal, rectal and urethral swabs and submitted this validation data to the New York State Department of Health.

New collection kits will be required and will be supplied in the next several weeks to clients. A Technical Bulletin is available outlining additional details regarding the change. There will be no changes to test codes used for ordering this assay. Please continue to order test code 6842, with the source clearly indicated, for amplified C. trachomatis and N. gonorrhoeae testing.

For additional information please refer to: http://acmlab.com/Resource-Library/